Han Chu Lee

Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial

Jordi Bruix, Tadatoshi Takayama, Vincenzo Mazzaferro et al. · The Lancet Oncology · 2015 · 1.1K citations

Medicine, Oncology, Surgery +17

Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial

Shukui Qin, Minshan Chen, Ann‐Lii Cheng et al. · The Lancet · 2023 · 488 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Efficacy and Safety of Transarterial Chemoembolization Plus External Beam Radiotherapy vs Sorafenib in Hepatocellular Carcinoma With Macroscopic Vascular Invasion

Sang Min Yoon, Baek‐Yeol Ryoo, So Jung Lee et al. · JAMA Oncology · 2018 · 454 citations · Full text

Pharmacy, Oncology, Hepatic Pharmacotherapy +11

HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability

Gi‐Ae Kim, Young‐Suk Lim, Jihyun An et al. · Gut · 2013 · 418 citations

Pharmacy, Pharmacology, Pharmacotherapy +16

Genomic portrait of resectable hepatocellular carcinomas: Implications of <i>RB1</i> and <i>FGF19</i> aberrations for patient stratification

Sung‐Min Ahn, Se Jin Jang, Ju Hyun Shim et al. · Hepatology · 2014 · 413 citations

Medicine, Genetics, Oncology +17